2024
Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis
Wang P, Yang X, Zhang L, Sha S, Huang J, Peng J, Gu J, Pearson J, Hu Y, Zhao H, Wong F, Wang Q, Wen L. Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis. Nature Communications 2024, 15: 4232. PMID: 38762479, PMCID: PMC11102548, DOI: 10.1038/s41467-024-48611-8.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Gut microbiotaGut microbial communityTransferred to germ-free miceB cellsGerm-free miceTLR9 deficiencyKO miceGene sequencesGerminal center B cellsMicrobial communitiesMarginal zone B cellsGut dysbiosisFollicular helper cellsSelf-DNAMetabolic homeostasisAssociated with increased frequencyPro-inflammatory stateFat tissue inflammationGutHigh-fat dietMicrobiotaHelper cellsT cellsControl miceTLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model
Pearson J, Hu Y, Peng J, Wong F, Wen L. TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model. Frontiers In Immunology 2024, 15: 1333967. PMID: 38482010, PMCID: PMC10935730, DOI: 10.3389/fimmu.2024.1333967.Peer-Reviewed Original ResearchConceptsToll-like receptor 5Antigen-presenting cellsDendritic cellsType 1 diabetesTLR5-deficientDC developmentCytokine secretionCD4<sup>+</sup> T cell proliferationPathogenesis of type 1 diabetesT cell responsesEnhanced cytokine secretionT cell proliferationWild-type miceSusceptibility to obesitySusceptibility to T1DProinflammatory cytokine secretionGut microbiotaSpontaneous T1DNOD miceAutoimmune diabetesNon-obeseHuman T1DReceptor 5Autoimmune diseasesHyper-secretion
2023
Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells
Liu H, Zhang W, Xie L, Hu Y. Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells. Pharmaceuticals 2023, 17: 8. PMID: 38275994, PMCID: PMC10819697, DOI: 10.3390/ph17010008.Peer-Reviewed Original ResearchGeneration and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
Zhuang W, Zhang W, Xie L, Wang L, Li Y, Wang Z, Zhang A, Qiu H, Feng J, Zhang B, Hu Y. Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor. International Journal Of Molecular Sciences 2023, 24: 17631. PMID: 38139459, PMCID: PMC10743877, DOI: 10.3390/ijms242417631.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesSortilin 1Breast tumorsTumor antigen heterogeneityAdvanced breast tumorsSuperior safety profileAnti-tumor activityBreast tumor cell linesSafety profileADC targetBreast cancerCell cytotoxicityBystander killingTumor cell linesDrug resistanceAntigen heterogeneityTumorsPromising targetNew targetsTreatmentCell linesHER2Effective cytotoxicityTumor suppressionLysosomal traffickingSqualene Biosynthesis in Engineered Escherichia Coli
Zhang W, Li Y, Xie L, Hu Y. Squalene Biosynthesis in Engineered Escherichia Coli. Pharmaceutical Fronts 2023, 05: e321-e329. DOI: 10.1055/s-0043-1776291.Peer-Reviewed Original ResearchMevalonate pathwaySqualene productionProduction of squaleneEngineered Escherichia coliSqualene synthasesChassis cellsMVA pathwayDimethylallyl diphosphateEscherichia coli strainsExpression strengthMetabolic fluxExtinct animalsXL1-BlueDifferent speciesSqualene biosynthesisEscherichia coliColi strainsGenesPathwayNatural triterpenoidIspHGeneration of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
Zhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, Hu Y. Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal Of Molecular Sciences 2023, 24: 16056. PMID: 38003245, PMCID: PMC10671096, DOI: 10.3390/ijms242216056.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Low HER2 expressionHER2 expressionSortilin 1Antitumor efficacyEpidermal growth factor receptor 2MDA-MB-231 xenograft mouse modelTumor cellsGrowth factor receptor 2High HER2 expressionTreatment of patientsXenograft mouse modelFactor receptor 2Bispecific antibody-drug conjugatesAntibody-drug conjugatesTreatment of tumorsExpression tumorsMouse modelReceptor 2Bispecific antibody drugsToxic payloadsBispecific antibodiesTumorsNormal tissuesAntibody drugsNLRP6 deficiency expands a novel CD103+ B cell population that confers immune tolerance in NOD mice
Pearson J, Peng J, Huang J, Yu X, Tai N, Hu Y, Sha S, Flavell R, Zhao H, Wong F, Wen L. NLRP6 deficiency expands a novel CD103+ B cell population that confers immune tolerance in NOD mice. Frontiers In Immunology 2023, 14: 1147925. PMID: 36911699, PMCID: PMC9995752, DOI: 10.3389/fimmu.2023.1147925.Peer-Reviewed Original ResearchConceptsNlrp6-deficient miceType 1 diabetesNLRP6 deficiencyB cellsIL-10Non-obese diabetic (NOD) miceType 1 diabetes developmentRole of NLRP6Germ-free miceT cell proliferationB cell populationsIntestinal epithelial cellsBreg populationAutoimmune diabetesNOD miceCrohn's diseaseImmune toleranceDiabetes developmentDiabetic miceImmune cellsCD103Inflammasome proteinsImmune responseNLRP6Gut microbiota